Aims: To investigate the relationship between the sweet liking/sweet disliking phenotype (a putative probe of brain opioid function), craving for alcohol and response to treatment with naltrexone in individuals with alcohol dependence. Methods: Forty individuals with alcohol dependence were enrolled in a 12-week open-label study of 50 mg of naltrexone with four sessions of motivational enhancement therapy. Prior to treatment, individuals completed a sweet preference test and the Penn Alcohol Craving Scale. Subjects were categorized as sweet liking (SL), n = 15, or sweet disliking (SDL), n = 25, via a standard sweet tasting paradigm. The sweet tasting results were blinded to the subjects and to treatment staff. SL status, pretreatment cravin...
Reductions in cue-induced craving and subjective response to drugs of abuse are commonly used as ini...
During the first weeks of abstinence, alcohol craving in patients may increase or “incubate.” We hyp...
Naltrexone blocks the opioid receptors that modulate the release of dopamine in the brain reward sys...
Aims: To investigate the relationship between the sweet liking/sweet disliking phenotype (a putative...
Identification of moderators of the response to naltrexone hydrochloride treatment for alcohol depen...
International audienceObjectives: Craving plays an important role in the development and maintenance...
Background: Naltrexone (NTX) has proven to be effective with alcoholics in treatment, with most cont...
Naltrexone (NTX) is clinically efficacious at attenuating alcohol intake in non-abstinent alcoholics...
The opioid antagonist, naltrexone, is reported, in single centre studies, to improve the clinical ou...
Aim: To explore the effect of acamprosate and naltrexone on craving and alcohol consumption in the t...
BACKGROUND: Alcohol dependence is extremely common in patients with bipolar disorder and is associat...
Naltrexone (NTX) has been widely studied for the treatment of alcohol use disorder with overall supp...
Distinct environmental and conditioned stimuli influencing ethanol-associated appetitive and consumm...
Distinct environmental and conditioned stimuli influencing ethanol-associated appetitive and consumm...
Background It is well known that naltrexone, an FDA-approved medication for treatment of alcohol dep...
Reductions in cue-induced craving and subjective response to drugs of abuse are commonly used as ini...
During the first weeks of abstinence, alcohol craving in patients may increase or “incubate.” We hyp...
Naltrexone blocks the opioid receptors that modulate the release of dopamine in the brain reward sys...
Aims: To investigate the relationship between the sweet liking/sweet disliking phenotype (a putative...
Identification of moderators of the response to naltrexone hydrochloride treatment for alcohol depen...
International audienceObjectives: Craving plays an important role in the development and maintenance...
Background: Naltrexone (NTX) has proven to be effective with alcoholics in treatment, with most cont...
Naltrexone (NTX) is clinically efficacious at attenuating alcohol intake in non-abstinent alcoholics...
The opioid antagonist, naltrexone, is reported, in single centre studies, to improve the clinical ou...
Aim: To explore the effect of acamprosate and naltrexone on craving and alcohol consumption in the t...
BACKGROUND: Alcohol dependence is extremely common in patients with bipolar disorder and is associat...
Naltrexone (NTX) has been widely studied for the treatment of alcohol use disorder with overall supp...
Distinct environmental and conditioned stimuli influencing ethanol-associated appetitive and consumm...
Distinct environmental and conditioned stimuli influencing ethanol-associated appetitive and consumm...
Background It is well known that naltrexone, an FDA-approved medication for treatment of alcohol dep...
Reductions in cue-induced craving and subjective response to drugs of abuse are commonly used as ini...
During the first weeks of abstinence, alcohol craving in patients may increase or “incubate.” We hyp...
Naltrexone blocks the opioid receptors that modulate the release of dopamine in the brain reward sys...